Literature DB >> 25245571

Perinatal maternal probiotic intervention impacts immune responses and ileal mucin gene expression in a rat model of irritable bowel syndrome.

J Barouei1, M Moussavi1, D M Hodgson2.   

Abstract

Alterations in immune responses and intestinal secretory state are among features commonly observed in the maternal separation (MS) rat model of Irritable Bowel Syndrome. This study examined whether perinatal maternal introduction of probiotics influences plasma immune markers and ileal mucin-2 (MUC2) gene expression in rat offspring exposed to neonatal maternal separation (MS, 3 h/day, postnatal days (PND) 2-14) and/or subsequently to acute restraint stress in adulthood (AS, 30 min/day, PND 83-85). Data analysis indicated that stress protocols did not affect plasma tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ) and interleukin (IL)-6 levels in young offspring (PND 24) born to the vehicle-treated dams. Maternal probiotic intervention was associated with significantly decreased IFN-γ levels in young offspring compared with non-probiotic offspring (P≤0.05). It also induced a significant increase in IL-6 levels in MS pups (P≤0.05). Exposure of both non-MS and MS offspring to AS induced a significant increase in haptoglobin levels compared to controls (P≤0.05), whereas all offspring born to the probiotic-treated dams, irrespective of stress treatment conditions, exhibited significantly decreased haptoglobin levels to well below the control levels (P≤0.05). MS and/or AS did not affect ileal expression of MUC2 in offspring born to the non-probiotic treated dams. While maternal probiotic intake significantly downregulated ileal gene expression of MUC2 in MS male young offspring, it was associated with significantly upregulated MUC2 mRNA expression in MS or AS adult male offspring. These findings suggest that maternal probiotic intervention may exert long-lasting anti-inflammatory effects and impact gut outcomes in offspring at increased risk of dysfunctional gut.

Entities:  

Keywords:  IBS; MUC2; gene expression; immune response; rat model

Mesh:

Substances:

Year:  2015        PMID: 25245571     DOI: 10.3920/BM2013.0011

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  6 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes.

Authors:  Jamie M Joseph; Catrin Law
Journal:  Neurosci Biobehav Rev       Date:  2018-11-22       Impact factor: 8.989

3.  Bifidobacterium pseudocatenulatum CECT 7765 Ameliorates Neuroendocrine Alterations Associated with an Exaggerated Stress Response and Anhedonia in Obese Mice.

Authors:  Ana Agusti; A Moya-Pérez; I Campillo; S Montserrat-de la Paz; V Cerrudo; A Perez-Villalba; Yolanda Sanz
Journal:  Mol Neurobiol       Date:  2017-09-18       Impact factor: 5.590

Review 4.  Early-life stress and inflammation: A systematic review of a key experimental approach in rodents.

Authors:  Ethan G Dutcher; E A Claudia Pama; Mary-Ellen Lynall; Shahid Khan; Menna R Clatworthy; Trevor W Robbins; Edward T Bullmore; Jeffrey W Dalley
Journal:  Brain Neurosci Adv       Date:  2020-12-28

Review 5.  Biodetoxification and Protective Properties of Probiotics.

Authors:  Oana Lelia Pop; Ramona Suharoschi; Rosita Gabbianelli
Journal:  Microorganisms       Date:  2022-06-23

6.  Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats.

Authors:  Antonio Jesús Ruiz-Malagón; María José Rodríguez-Sanchez; María Jesús Rodríguez-Sojo; Teresa Vezza; Ivo Pischel; Francesca Algieri; María Elena Rodríguez-Cabezas; Alba Rodríguez-Nogales; Julio Gálvez
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.